Resources

Transcriptomic profile of adverse neurodevelopmental outcomes after neonatal encephalopathy

Nature Genetics, Sci Rep 10, 13100 (2020).

A rapid and early diagnostic test to identify the encephalopathic babies at risk of adverse outcome may accelerate the development of neuroprotectants. We examined if a whole blood transcriptomic signature measured soon after birth, predicts adverse neurodevelopmental outcome eighteen months after neonatal encephalopathy. We performed next generation sequencing on whole blood ribonucleic acid obtained within six hours of birth from the first 47 encephalopathic babies recruited to the Hypothermia for Encephalopathy in Low and middle-income countries (HELIX) trial.

  https://www.nature.com/articles/s41598-020-70131-w

 

Considering Genomic Research?
*
 
*
*
 


2020 © MedGenome • All Rights Reserved